Hypoxia/oxidative stress alters the pharmacokinetics of CPU86017-RS through mitochondrial dysfunction and NADPH

Jie Gao1, Xuan-sheng Ding, Yu-mao Zhang

  • 1Faculty of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.

Abstract

Insights

Hypoxia and oxidative stress alter antiarrhythmic CPU86017-RS pharmacokinetics by affecting mitochondrial function and increasing ER stress. Apocynin or N-acetylcysteine (NAC) can reverse these effects.

Area of Science:

  • Pharmacology
  • Cardiovascular Research
  • Biochemistry

Background:

  • Hypoxia and oxidative stress can significantly impact drug pharmacokinetics (PK).
  • CPU86017-RS is a novel antiarrhythmic agent whose PK may be affected by these conditions.
  • Understanding these alterations is crucial for effective therapeutic use.

Purpose of the Study:

  • To investigate the mechanisms by which hypoxia/oxidative stress alter the PK of CPU86017-RS.
  • To identify potential therapeutic interventions to mitigate these changes.

Main Methods:

  • Male and female Sprague-Dawley rats were exposed to hypoxia or isoproterenol (ISO) to induce stress.
  • CPU86017-RS was administered, and PK parameters and tissue distribution were analyzed.
  • Levels of key proteins involved in oxidative stress (Mn-SOD, NOX) and ER stress (ATF-6, PERK) were measured.
  • In vitro studies using liver microsomes assessed drug metabolism.

Main Results:

  • Hypoxia significantly increased CPU86017-RS Cmax, t1/2, MRT, and AUC, associated with reduced Mn-SOD and increased ER stress markers and NOX.
  • ISO-induced stress increased CPU86017-RS tissue distribution and NOX levels.
  • Apocynin (NOX blocker) and N-acetylcysteine (NAC) reversed the PK and distribution abnormalities.
  • In vitro metabolism of CPU86017-RS was reduced under hypoxic conditions and restored by NAC.

Conclusions:

  • Hypoxia/oxidative stress alter CPU86017-RS PK and metabolism via mitochondrial dysfunction, NOX activation, and ER stress.
  • Apocynin and NAC effectively alleviate these stress-induced abnormalities.
  • These findings suggest strategies to manage CPU86017-RS therapy in patients experiencing hypoxia or oxidative stress.

Related Concept Videos

Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
11.9K
Bioactivation and Tissue Toxicity01:25

Bioactivation and Tissue Toxicity

Bioactivation is a metabolic process that transforms less reactive substances into highly reactive metabolites, initiating tissue toxicity. This transformation can lead to various toxic effects, including carcinogenesis and teratogenesis. Reactive metabolites are classified into two main types: electrophiles and free radicals.Electrophiles are electron-deficient species and are produced primarily by the enzyme cytochrome P-450 during the metabolism of compounds containing carbon, nitrogen, or...
168
The Electron Transport Chain01:30

The Electron Transport Chain

The electron transport chain or oxidative phosphorylation is an exothermic process in which free energy released during electron transfer reactions is coupled to ATP synthesis. This process is a significant source of energy in aerobic cells, and therefore inhibitors of the electron transport chain can be detrimental to the cell's metabolic processes.
Inhibitors of the electron transport chain
Rotenone, a widely used pesticide, prevents electron transfer from Fe-S cluster to ubiquinone or Q...
13.9K
Phase I Oxidative Reactions: Overview01:19

Phase I Oxidative Reactions: Overview

Phase I biotransformation, or functionalization, is a crucial chemical process that converts drugs and other xenobiotics into more water-soluble forms, facilitating expulsion from the body. It involves oxidative, reductive, and hydrolytic reactions that add or unveil polar functional groups on lipophilic substrates. Key players in phase I reactions are the mixed-function oxidases. Situated in liver cell microsomes, these enzymes predominantly carry out drug metabolism. They require molecular...
1.0K
Drug Metabolism: Phase I Reactions01:17

Drug Metabolism: Phase I Reactions

A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
5.1K
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
245